Select your Market
{{ userContent.title }}
Financial results for 2024
Forecast 2025
| 2024 (in € billion) | Change (in %, compared to 2023) | Organic change (in %, compared to 2023) |
|---|---|---|---|
Group net sales | 21.2 | 0.8 | 2.0 |
EBITDA pre | 6.1 | 3.3 | 6.9 |
Life Science sales | 8.9 | −3.9 | −3.3 |
Healthcare sales | 8.5 | 5.0 | 7.0 |
Electronics sales | 3.8 | 3.4 | 4.6 |
“We are back on a growth path with all three businesses. In 2025, we will continue to deliver profitable growth across our company. With our innovation-driven portfolio, we are ideally positioned to benefit from global macro trends.”
Our CEO Belén Garijo comments on the full-year 2024 results.
Detailed information about the development of our business for 2024.
Downloads for the Media
Press Releases
The Group returned to profitable growth in 2024 and delivered on its guidance for the year.
2025/03/06
Our Q1 2025 results will be published on May 15, 2025, at 7 a.m. (CET). Our conference call for the media will take place at 10:00 a.m. (CET), and the conference call for analysts at 2 p.m. (CET).
Our Q2 2025 results will be published on August 7, 2025, at 7 a.m. (CEST). Our conference call for the media will take place at 09:30 a.m. (CEST), and the conference call for analysts at 2 p.m. (CEST).
Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more
